Stock comparison
Ironwood Pharmaceuticals
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IRWD
Ironwood Pharmaceuticals
Market cap
$645.28M
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IRWD | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 47D | 77B | LMAT |
| Benjamin Graham | 25F | 89A | LMAT |
| Philip Fisher | 41D | 81C | LMAT |
| Peter Lynch | 26F | 67B | LMAT |
| Joel Greenblatt | 69B | 56D | IRWD |
| Charlie Munger | 68D | 68D | Tie |
| Terry Smith | 66C | 69D | LMAT |
Side-by-side metrics
| Metric | IRWD | LMAT |
|---|---|---|
| Market cap | $645.28M | $2.23B |
| P/E (TTM) | 4.5x | 37.1x |
| EV/EBIT | 9.0x | 36.6x |
| ROIC (TTM) | 43.86% | 9.43% |
| Gross margin | 99.75% | 72.39% |
| Net margin | 41.76% | 24.35% |
| Revenue CAGR 5y | -8.02% | 12.75% |
| EPS CAGR 5y | -53.69% | 19.04% |
| Debt / Equity | - | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IRWD leads on
- Debt / Equity-vs 0.5x+117%
- P/E (TTM)4.5xvs 37.1x+88%
- ROIC (TTM)43.86%vs 9.43%+78%
- EV/EBIT9.0xvs 36.6x+76%
LMAT leads on
- Revenue CAGR 5y12.75%vs -8.02%+163%
- EPS CAGR 5y19.04%vs -53.69%+135%
- Dividend yield0.84%vs 0.0%+100%
- Market cap$2.23Bvs $645.28M+71%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.